Preparation of RF

A total of 89 chemicals were quickly and accurately identified from RF (Additional file 1: Fig. S1), via comparison with the retention times and MS/MS spectra of the reference standards, reference literatures, Chemical Book and other databases. The detailed information of the identified chemical constituents in RF were listed Additional file 1: Table S2. And then under the optimal conditions described above, the total ion chromatograms (TICs) of RF and target reference standards in negative mode were shown in Fig. 1. The contents of targeted markers gallic acid, isoquercitrin, ellagic acid, hyperoside, rutin, quercetin, kaempferol-3-rutinoside, luteolin and tiliroside in RF were determined as 6.056 mg/g, 0.026 mg/g, 18.390 mg/g, 0.142 mg/g, 0.377 mg/g, 0.929 mg/g, 1.591 mg/g, 0.0006 mg/g and 1.381 mg/g, respectively.

RF alleviates CCl4-induced liver damage and inflammatory injury in mice

CCl4 is a strong hepatotoxin that causes lipid peroxidation in hepatocytes, leading to activation of HSCs, disturbances in lipoproteins synthesis, damage to mitochondria, and disorders in lipid metabolism in hepatocytes [28]. Moreover, the prolonged stimulation of CCl4-induced the accumulation of Col1A1 in the liver leads to liver fibrosis. CCl4, as a liver injury and fibrosis promotor, is widely used for establishing animal liver fibrosis models [29,30,31]. We used a mouse liver fibrosis model developed by intraperitoneal injection of CCl4 and harvested tissues after the last RF treatment with doses of 450 and 900 mg·kg− 1 to explore the anti-fibrosis efficacy of RF.

Pathological changes in the liver were observed after the experiment (Fig. 2A). The liver of normal mice has a normal brilliant red appearance, with a smooth surface and soft and elastic texture, and no noticeable swelling. The liver was found to have a rough, elevated grain surface, was more fragmented, and noticeably swollen after CCl4 induction. The surface of the liver was smoother, the texture was softer, and there was no apparent swelling after RF therapy compared to the model group. H&E staining revealed abnormalities in liver histopathology in mice (Fig. 2B). The results revealed morphological abnormalities in the livers of CCl4-induced mice, including hepatic cord disorder, lobular structure disorder, hepatocyte swelling and degeneration, and a significant number of inflammatory cells infiltration in the portal zone. The dose-dependent decrease of CCl4-induced hepatic pathological abnormality was seen after 3 weeks of RF treatment.

Fig. 1
figure 1

Structural elucidation of the extract of Rubus chingii Hu. unripe fruits (RF) using UHPLC-Q-Exactive Orbitrap HRMS. A the total ion chromatograms (TICs) of RF in negative mode; B TICs of mixture reference standards in negative mode; C the chemical structures of target reference standards

Fig. 2
figure 2

RF alleviates CCl4-induced liver damage, inflammatory injury and liver fibrosis in mice. A Representative photographs of livers in each group. B H&E (× 200) staining and C Sirius red (× 100) staining. Serum activities of D ALT and E AST. Liver F TNF-α, G MCP-1, H IL-1β, and I IL-6 levels. J Sirius red-positive area (%). K Hyp content. The results are expressed as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 versus the CCl4 group

Clinically, the levels of ALT and AST, two typical serum markers of liver injury, are often used to evaluate liver function indirectly. In comparison to the control group, serum ALT (p < 0.001, Fig. 2D) and AST (p < 0.01, Fig. 2E) levels were observed to increase in mice with CCl4-induced fibrosis, indicating that the hepatocytes are damaged. After RF treatment, both RFL and RFH can lead to a significant decrease in serum ALT (p < 0.05 for RFL; p < 0.01 for RFH) and AST (p < 0.01 for RFL; p < 0.01 for RFH) levels. These results demonstrate that RF can cause a significant improvement in liver injury.

Chronic inflammation has a significant role in the progress of hepatic fibrosis and is thought to be a key mediator. Overproduction of proinflammatory cytokines damages hepatocytes directly and promotes liver fibrosis with the gradual replacement of the scar tissue with the normal hepatocyte structure [32]. We examined the effectiveness of RF in inhibiting chronic inflammation by measuring the levels of TNF-α, MCP-1, IL-1β, and IL-6 in liver tissue by ELISA assay. The results indicated that the pro-inflammatory factors TNF-α (p < 0.001, Fig. 2F), MCP-1 (p < 0.001, Fig. 2G), IL-1β (p < 0.001, Fig. 2H), and IL-6 (p < 0.001, Fig. 2I) were expressed in significantly higher levels in the CCl4 model group (p < 0.001) than in the normal control group. RF-treated mice, on the other hand, had considerably lower levels of these inflammatory factors (p < 0.05, p < 0.01, or p < 0.001). These results suggest that RF caused a reduction in the inflammatory levels in CCl4-induced liver fibrosis mice.

RF alleviates CCl4-induced liver fibrosis in mice

Collagen fibers in the liver continue to accumulate during the fibrosis process. Sirius red dye is an acidic solid anion dye that readily binds to the basic groups of collagen molecules. Collagen is stained red under a regular light microscope, while muscle fibers and cytoplasm are dyed yellow. Sirius red staining is frequently employed in liver fibrosis models for semi-quantitative measurement of collagen fibrous deposition. Red collagen fiber deposition was uncommon in the normal group, as illustrated in Fig. 2C. In the model group, a considerable number of red collagen fibers were deposited around the portal region and created a thick fibrous septum, some of which penetrated deep into the liver’s interior lobules, as compared to the normal group. After RF treatment, there was still more collagen fibrous deposition in the portal area in the RFL group, but fewer collagen fibers and fibrous septum than in the model group. In the RFH group, the collagen fibrous fibers were significantly reduced and confined to the portal area. Furthermore, sirius red-positive area (SR) was calculated to evaluate collagen deposition in hepatic fibrosis (Fig. 2J). When compared to the CCl4 treatment group, SR was considerably reduced after treatment with RF and Sorafenib (p < 0.01 for RFL; p < 0.001 for RFH; and p < 0.05 for Sorafenib). The results suggested that RF can alleviate the collagen fibrous deposition induced by CCl4 in the liver, thus improving liver fibrosis progression.

Collagen is continuously accumulated in liver fibrosis and is composed of 18 kinds of amino acids, among which Hyp is the prevalent amino acid in collagen. Consequently, the determination of Hyp content can reflect the level of liver collagen accumulation, which can then be used to determine the degree of liver fibrosis [33, 34]. Compared to the control group, the CCl4 group had significantly higher Hyp content (p < 0.001, Fig. 2K), indicating the excessive collagen deposition in the liver during fibrosis, which is consistent with previous findings. After RF and Sora treatment, Hyp content was distinctly reduced (p < 0.01 for RFL and Sora; p < 0.001 for RFH). As a result, the findings imply that RF is critical in preventing collagen deposition during fibrosis. These findings show that RF substantially reduces liver fibrosis in CCl4-induced mice.

RF ameliorates the expressions of α-SMA and Col1A1 in the liver of mice with CCl4-induced liver fibrosis

In the case of liver fibrosis, HSCs are the predominant cell type that participates in excessive collagen formation. The activation of HSCs is a critical event in liver fibrosis and inhibiting it is crucial for fibrosis relief [35]. Activated HSCs can be transformed into myofibroblasts with the properties of promoting fiber proliferation, and then the expressions of α-SMA and Col1A1. The higher the activation degree of HSCs, the higher levels of α-SMA and Col1A1 will be, or conversely, the lower levels of α-SMA and Col1A1 [36]. As a result, α-SMA and Col1A1 are commonly used as markers to assess HSCs activation, with α-SMA being the most commonly used marker.

Thus, in this study, α-SMA and Col1A1 were evaluated in HSCs activation. The expressions of α-SMA and Col1A1 on the protein levels were studied through immunohistochemistry, immunofluorescent and western blot assay. The expressions of α-SMA (Fig. 3A) and Col1A1 (Fig. 3B) were elevated greatly in the CCl4 group compared the control group in immunofluorescent assays. In contrast, the expressions of α-SMA and Col1A1 were suppressed in the RF and Sora treatment. Immunohistochemistry testing yielded identical results, as expected. In the normal group, α-SMA (Fig. 3C) and Col1A1 (Fig. 3D) were only slightly expressed around the blood vessels (the positive substance was brownish-yellow). Compared with the normal group, α-SMA (p < 0.001, Fig. 3F) and Col1A1 (p < 0.001, Fig. 3G) were significantly expressed in the fibrous septa and portal region in the model group. After RF and Sora treatment, in comparison to the model group, α-SMA (p < 0.05 for RFL; p < 0.01 for RFH; p < 0.05 for Sora) and Col1A1 (p < 0.05 for RFL, RFH and Sora) were significantly reduced. Western blot assay was employed to analyze the expression level of α-SMA protein (Fig. 3E). It was found that RF and Sora could cause a significant reduction in the expression level of α-SMA protein (p < 0.05 for RFL; p < 0.001 for RFH; p < 0.01 for Sora, Fig. 3H). In brief, the above results suggested that RF can ameliorate the activation of HSCs, which may be the potential mechanistic pathway regulating its liver fibrosis-mitigating impact in vivo.

Fig. 3
figure 3

RF attenuates the expressions of α-SMA and Col1A1 in the liver of mice with CCl4-induced liver fibrosis. Representative immunofluorescence staining of A α-SMA and B Col1A1, the nuclei were counterstained with DAPI, representative confocal microscopy images are shown, scale bar = 200 μm. Representative immunohistochemical staining of C α-SMA and D Col1A1, scale bar = 100 μm. Quantification of histological changes of F α-SMA and G Col1A1 with positive area using Image J analysis software (n = 3). The expression of α-SMA was examined by E western blot assay and H its quantitative analysis (n = 3). The results are expressed as the mean ± SD. *p < 0.05, ** p < 0.01, *** p < 0.001 versus the CCl4 group

RF inhibits TGF-β/Smads signaling pathway

Activation of HSCs is regulated via various growth factors and inflammatory cytokines released from the impaired hepatocytes. Several cytokines are involved in the transformation and proliferation of HSCs, with TGF-β1 being the most effective [37, 38]. TGF-β1 is also involved in almost all stages of liver fibrosis. TGF-β1 can promote ECM synthesis, and inhibit the degradation of newly generated ECM, thereby disrupting ECM’s natural equilibrium and resulting in over-position of ECM and eventually exacerbated liver fibrosis. TGF-β1 promotes liver fibrosis formation through various mechanisms, among which the TGF-β/Smads signaling pathway has a key involvement in the progress of liver fibrosis by promoting HSCs transdifferentiation and migration [37]. TβRII receptor on the cell membrane binds to the activated TGF-β1, recognizing the TβRI receptor and phosphorylates at its glycine-serine enrichment region. Then, Smad2/3 protein is phosphorylated by the activated TβRI receptor and binds to Smad4 protein to form the Smads complex, which enters the nucleus. Smad4 enhances the activity of the Smad3 reaction promoter and promotes the formation and development of fibrosis by regulating the ability of Smad3 protein to transcriptome its target gene. After the Smads complex enters the nucleus, it binds to the target genes related to fibrosis. It regulates their transcription and expression to promote the activation of HSCs, thus promoting the occurrence of liver fibrosis [39,40,41]. As a result, inhibiting the TGF-β/Smads signaling pathway may be an effective strategy for inhibiting the activation of HSCs, thereby preventing the formation and progression of liver fibrosis.

Our findings were confirmed by western blot assays of TGF-β/Smads signaling pathway-related proteins, including TGF-β1, Smad2/3, p-Smad2/3, and Smad4 (Fig. 4A). The protein expressions of TGF-β1 (p < 0.01, Fig. 4B), p-Smad2/3/Smad2/3 (p < 0.05, Fig. 4C), and Smad4 (p < 0.01, Fig. 4D) in the CCl4-induced fibrosis group were significantly higher than those in the control group. RF and Sora treatment clearly reduced the expression of TGF-β1 (p < 0.05 for RFL; p < 0.01 for RFH; p < 0.05 for Sora), p-Smad2/3/Smad2/3 (p < 0.05 for RFL; p < 0.01 for RFH; p < 0.05 for Sora) and Smad4 (p < 0.05 for RFL; p < 0.01 for RFH). The results suggested that RF inhibited TGF-β1 expression, and decreased the expressions of downstream signaling molecules p-Smad2/3 and Smad4 protein, which means the signal transduction ability of TGF-β1 was weakened, and then inhibited the activation and proliferation of HSCs, to play an anti-fibrosis role. The inhibitory effect of RF was concentration-dependent, and the higher the concentration of RF, the greater the inhibitory effect on the TGF-β/Smads signaling pathway, according to the results. The present findings revealed that RF strongly inhibits the TGF-β/Smads signaling pathway, which is linked to the relief of CCl4-induced hepatofibrogenesis in mice.

Fig. 4
figure 4

RF down-regulates TGF-β/Smads signaling pathway. The expression of A TGF-β1, p-Smad2/3, Smad2/3 and Smad4 were examined by western blot assay. Quantitative analysis of B TGF-β1, C p-Smad2/3/ Smad2/3, and D Smad4 expressions (n = 3). The results are expressed as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 versus the CCl4 group

RF ameliorates gut microbial dysbiosis in CCl4-induced hepatic fibrosis mice

With the advancement of research in the realm of gut microbiota, the precise link between gut microbiota and various diseases is becoming more apparent [10, 42, 43]. The liver is the organ that has the most direct interaction with the intestinal system and is therefore exposed to many bacterial components. The dysbiosis of the microbiome has been linked to a variety of liver diseases, and it may influence the degree of hepatic steatosis, inflammation, and fibrosis [11, 39, 44]. The CCl4-induced hepatic fibrosis model has been frequently utilized to assess the potential of natural compounds for liver protection due to its excellent reproducibility. In addition to leading to lipid peroxidation in liver cells, the gut microbiota has also been played a potentially important role in CCl4-induced liver fibrosis [45,46,47]. The community structure of the gut microbiota has been demonstrated to change when CCl4 is administered orally or intraperitoneally to induce hepatic fibrosis [45,46,47,48]. Dapito et al. found that the incidence of liver injury, fibrosis, and hepatocellular carcinoma induced by CCl4 was significantly lower in germ-free mice than in normal mice [49]. Mazagova et al. reported that the symbiotic microbiota might prevent hepatic fibrosis in germ-free mice induced by CCl4 [50], indicating that the gut microbiota is critical in developing CCl4-induced liver fibrosis and that regulating the gut microbiota may be beneficial in alleviating liver fibrosis. Therefore, we investigated the effect of RF on the structure and composition of gut microbiota to see if its protection against liver fibrosis is associated with the modulation of intestinal flora imbalance.

To examine the regulatory influence of RF on gut microbiota, we used the Illumina MiSeq technology to perform a pyrosequencing-based analysis of bacterial 16 S ribosomal RNA from variable regions V3–V4 of fecal samples. After removing the unqualified sequences, high-throughput pyrosequencing yielded an aggregate of 1,658,632 high-quality sequences from 28 fecal specimens (Additional file 1: Table S1). The Venn diagram highlighted how OTUs in the gut microbiota overlapped in different samples. A total of 647 OTUs were obtained from the samples using a 97% sequence similarity criterion, including 604 in the normal group, 564 in the model group, 542 in the RFL group, and 533 in the RFH group (Fig. 5A). 65 OTUs were found in the normal group but not in the model group, with 42 of these being found in the RFL and RFH groups. PCoA was used to estimate the level of similarity among gut microbiota compositions in four groups based on the weighted UniFrac distance of OTU abundance (Fig. 5B). There was a distinct grouping of gut microbial compositions for the normal and model groups. The RFL and RFH groups were grouped apart from the model group, indicating that RF caused a notable alteration in gut microbiota composition.

Fig. 5
figure 5

RF ameliorates gut microbial dysbiosis in CCl4-induced hepatic fibrosis mice. A Venn graph of the OTUs from gut microbiota of four groups. B Weighted UniFrac PCoA analysis of gut microbiota based on the OTU data of four groups. C The percent of community abundance on phylum-level in each mouse of four groups. Relative abundance of D Actinobacteriota and E Firmicutes in fecal microbiota in four groups. *p < 0.05, **p < 0.01 versus the CCl4 group

To evaluate the general structural framework of the bacterial community in various groups, we studied the extent of similarity of bacterial taxonomy at the phylum and genus levels. Firmicutes, Bacteroidetes, and Actinobacteriota were among the most prevalent phyla in the fecal microbiota community at the phylum level (Fig. 5C). The relative abundance of Actinobacteriota decreased (3.0 ± 1.2% vs. 11.5 ± 5.2%, p < 0.01, Fig. 5D) and that of Firmicutes increased (45.4 ± 6.1% vs. 35.2 ± 4.8%, p < 0.05, Fig. 5E) in the model group, in comparison to the normal group. Supplementation with RF did not significantly affect Firmicutes abundance (41.5 ± 10.1% vs. 45.4 ± 6.1% for RFL, p > 0.05; 40.8 ± 8.3% vs. 45.4 ± 6.1% for RFH, p > 0.05), but prevent the decrease of Actinobacteriota (4.3 ± 1.1% vs. 3.0 ± 1.2% for RFL, p < 0.05; 12.7 ± 4.1% vs. 3.0 ± 1.2% for RFH, p < 0.01) that was induced by the CCl4, suggesting that RF has the potential to carve the structure of gut microbiota.

At the genus level, 137 species of bacteria genera were discovered in the four sets of specimens, with 18 genera identified as the dominant genera with more than 1% relative abundance. Circos of dominating genera (Fig. 6A) and the LEfSe analysis further demonstrated that RF supplementation reversed the gut microbiota profile changes induced by CCl4. According to log10 LDA > 2.0, CCl4 had a substantial impact on 31 bacterial genera, with 24 genera having lower abundance and 7 genera having a higher abundance than the control group (Fig. 6B). Furthermore, this impact was clearly seen in three of the 31 bacterial taxa with log10 LDA > 4.0. Specifically, Bifidobacterium and Turicibacter were depleted remarkably upon exposure to CCl4, whereas Lactobacillus was enriched remarkably. A comparison between RFL and the model group showed that 5 genera (including Dubosiella, Bifidobacterium, Parabacteroides) were higher, and 10 genera were lower in the RFL group compared to the model group (Fig. 6C). For example, Dubosiella, Bifidobacterium, and Parabacteroides were elevated by RFL administration, alongside a decrease in Paludicola, Prevotellaceae_UCG-001, Ileibacterium. Further comparison between RFH and the model group showed that 6 genera were enriched and 10 genera were decreased in the RFH group than in the model group (Fig. 6D). For example, Bifidobacterium, Dubosiella, and Turicibacter were elevated by RFH administration, accompanied by a reduction in Prevotellaceae_UCG-001, Ruminococcus_torques_group, Norank_f_Desulfovibrionaceae. Collectively, a total of 18 different bacterial genera were increased or decreased by RF administration, and all these results indicated that RF administration restored the CCl4-induced imbalance of the gut microbiota to the levels of the normal group, RF at an elevated concentration manifested a more excellent capability in comparison the lower concentration.

Fig. 6
figure 6

RF ameliorates gut microbial dysbiosis on genus level. A Circos diagram of microbial distributions on genus level for four groups. The LEfSe analysis of the gut microbiota differed between two groups (B Normal and Model groups; C Model and RFL groups; D Model and RFH groups). The statistical test was performed using LDA effect size method. The histogram showed the lineages with LDA values of 2.0 or higher as determined by LEfSe

Correlation analysis between gut microbiota and liver fibrosis indexes

Liver fibrosis has predisposed to gut microbiome dysfunction in animal models and patients [47, 51]. By promoting intrahepatic inflammatory responses and activating Toll-like receptor (TLR) related pathways, dysfunctional gut microbiota can aggravate liver fibrosis [52, 53]. Alleviating the gut microbiota disorder in liver fibrosis will improve liver inflammation and fibrosis, indicating the potential of regulating gut microbiota as a therapeutic or diagnostic method for liver fibrosis [51]. Our findings are consistent with those of other research in which the gut microbiota of CCl4-induced liver fibrosis mice was reported to be disrupted [45,46,47], and the supplementation of RF can effectively ameliorate liver fibrosis induced by CCl4 while modulating the gut microbiota simultaneously. To determine the interrelation between the gut microbiota-regulating effects of RF and its advantageous impact on liver fibrosis, we performed a spearman’s rank correlation analysis on 18 altered bacterial genera (Aerococcus, Akkermansia, Anaerostipes, Bifidobacterium, Burkholderia-Caballeronia-Paraburkholderia, Coriobacteriaceae_UCG-002, Dubosiella, Ileibacterium, Muribaculum, norank_f_Desulfovibrionaceae, norank_f_Flavobacteriaceae, norank_f_norank_0_norank_c_Clostridia, Paludicola, Parabacteroides, Prevotellaceae_UCG-001, Ruminococcus, Ruminococcus_torques_group, Turicibacter) through the RF as well as 4 pharmacodynamics parameters (ALT, AST, Hyp, SR) to determine whether there was a relationship. According to the findings, 8 bacterial genera were found to be significantly correlated with at least one pharmacodynamics parameter (p < 0.05). A total of 19 cases were found to be significantly associated (p < 0.05, Fig. 7A), of which Bifidobacterium (for ALT, r = − 0.66, p = 0.0001, Fig. 7B; for AST, r = − 0.65, p = 0.0002, Fig. 7C; for Hyp, r = − 0.76, p < 0.0001, Fig. 7D; for SR, r = − 0.68, p < 0.0001, Fig. 7E), and Turicibacter (for ALT, r = − 0.80, p < 0.0001, Fig. 7F; for AST, r = − 0.52, p = 0.0047, Fig. 7G; for Hyp, r = − 0.63, p = 0.0003, Fig. 7H; for SR, r = − 0.57, p = 0.0017, Fig. 7I) were found to be the two most pertinent bacterial genera. It indicates that Bifidobacterium and Turicibacter are linked to hepatic fibrosis severity. By altering the composition of the gut microbial population and partially boosting Bifidobacterium and Turicibacter, RF alleviated CCl4-induced hepatic fibrosis.

Fig. 7
figure 7

The correlation analysis of altered bacterial genera and pharmacodynamics parameters. A Spearman’s correlation between 18 altered bacterial genera by RF (Aerococcus, Akkermansia, Anaerostipes, Bifidobacterium, Burkholderia-Caballeronia-Paraburkholderia, Coriobacteriaceae UCG-002, Dubosiella, Ileibacterium, Muribaculum, norank_f_Desulfovibrionaceae, norank_f_Flavobacteriaceae, norank_f_norank_0_norank_c_Clostridia, Paludicola, Parabacteroides, Prevotellaceae_UCG-001, Ruminococcus, Ruminococcus_torques_group, Turicibacter) and 4 pharmacodynamics parameters (ALT, AST, Hyp, SR), the color scale represents the spearman r value, with blue and orange indicating positive and negative correlations, respectively, and *p < 0.05, ** p < 0.01, *** p < 0.001. Correlations of Bifidobacterium abundance with B ALT, C AST, D Hyp and E SR. Correlations of Turicibacter abundance with F ALT, G AST, H Hyp and I SR

Fig. 8
figure 8

Proposed mechanism of RF in ameliorating CCl4-induced liver fibrosis. The red up arrow (↑) and red down arrow (↓) represent up-regulating and down-regulation effects of RF, respectively

According to the current study results, the higher Bifidobacterium and Turicibacter populations may be the two bacteria predominantly associated with RF’s anti-fibrosis effects on the liver. Bifidobacterium has been found as a probiotic that is practically ubiquitous in humans and is capable of producing anti-inflammatory short-chain fatty acids (SCFAs) [54]. Supplementing with Bifidobacterium has been shown to help alleviate liver steatosis, steatohepatitis, and fibrosis [55, 56]. Except for a few research that discovered changes in their abundance during liver fibrosis, there have been few investigations that have revealed Turicibacter’s specific role in liver fibrosis. Even though the precise functions of Bifidobacterium and Turicibacter, as well as their mechanism of action on liver fibrosis, are unknown, the available research suggests that raising Bifidobacterium and Turicibacter abundance can help with hepatic fibrosis recovery. Ursolic acid was found to prevent liver fibrosis in CCl4-induced liver fibrosis mice by suppressing HSC activation, correcting the gut microbiota imbalance, and increasing Bifidobacterium abundance [57]. Zhang et al. reported that mice with CCl4-induced acute liver injury had fewer Turicibacter, intake of an active substance-goats’ milk could protect against acute CCl4-induced hepatic injury, as evidenced by lower ALT and AST levels in serum, while also improving the gut microbiota imbalance, including an increase in Turicibacter abundance [48]. Our findings supported the notion that RF’s ability to regulate the gut microbial community, in part by increasing Bifidobacterium and Turicibacter, is associated with its anti-liver fibrosis effects. However, the molecular mechanism of RF affecting gut microbiota and its interaction with hepatic fibrosis needs further exploration. The current work demonstrates that RF has the potential to be developed as a novel prospective active agent for the treatment of liver fibrosis, and it offers a non-toxic and highly effective biological strategy for enriching the beneficial Bifidobacterium (Fig. 8).

In additional, oil-water partition coefficient (Log P) is an important material property of drugs. The dissolution, absorption, distribution, and transport of drugs in the body are related to their water solubility and lipid solubility. In present study, the Log P of target markers were obtained from literatures and professional databases (shown in Additional file 1: Table S3) [58,59,60], and the lipid solubility of these targeted markers were luteolin > tiliroside > kaempferol-3-rutinoside > quercetin > ellagic acid > isoquercitrin > hyperoside > rutin > gallic acid. As we all know, the lipid-soluble chemical components are more easily absorbed into the blood or into the body of intestinal bacteria through biological membranes. And then these components might be partially reversed the biochemical abnormalities and improved the associated gut microbiota imbalance. The water-soluble glycosides in the targeted markers might been have long retention time in the intestine, and these compounds could affect the composition of intestinal bacteria, and might be deglycosylated metabolism to lipid solubility aglycones by the intestinal bacteria. The complex interaction between the chemical components of traditional Chinese medicine and intestinal bacteria might be a difficulty in clarifying the pharmacodynamic mechanism of traditional Chinese medicine, and it might also be a breakthrough in analyzing the mechanism of traditional Chinese medicine, which is worthy of further research and exploration.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Disclaimer:

This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

Click here for Source link (https://www.biomedcentral.com/)